Access cutting-edge acquired hemophilia a treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access acquired hemophilia a specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related acquired hemophilia a treatment provided free
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
Sponsor: University of Washington
Check if you qualify for this acquired hemophilia a clinical trial in Washington Dc, DC
If you're searching for acquired hemophilia a treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acquired hemophilia a specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.